Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM)

Protocol No
IMF-BS001-ASCENT
Principal Investigator
Binod Dhakal
Phase
II
Summary
The main purpose of this study is to evaluate the effectiveness and safety of the combination of Carfilzomib, Lenalidomide, Daratumumab, and Dexamethasone as a treatment option for patients with Smoldering Multiple Myeloma.
Description
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: